Clinical Trial Update: SGLT2i in Kidney Stones [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 clinical trial at the University of Chicago is evaluating an SGLT2 inhibitor for nephrolithiasis and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nephrolithiasis

Drugs mentioned

• SGLT2 inhibitor

Snippet

Sponsor: University of Chicago | Conditions: Kidney Stones | EARLY_Phase 1 | Status: RECRUITING